Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cencora (COR) to $354 from $337 and keeps an Overweight rating on the shares. The firm views Q3 2025 results, particularly the earnings growth acceleration in U.S. Healthcare, as encouraging. Wells sees commentary on 2026 as pragmatic and typical for Cencora and doesn’t believe the company has line of sight to any discrete driver of moderation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: